NCCM
AKBA icon

Nine Chapters Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Nine Chapters Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-50,900
Closed -$492K – 26
2015
Q3 		$492K Sell
50,900
-10,400
-17% -$95.4K 0.04% 568
2015
Q2 		$631K Buy
+61,300
New +$523K 0.05% 495

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Nine Chapters Capital Management's AKBA Position: Q4 2015 in Review

Nine Chapters Capital Management sold out of Akebia Therapeutics (AKBA) in Q4 2015, closing a stake of 50,900 shares — an estimated $492K sold.

Nine Chapters Capital Management first reported a position in AKBA in Q2 2015 and held it in 2 quarters. The position peaked at $631K in Q2 2015. 90 funds tracked by Wall St. Rank hold AKBA as of Q4 2015.

  • Nine Chapters Capital Management reported no remaining Akebia Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 50,900 Akebia Therapeutics shares in Q4 2015, an estimated $492K.
  • Nine Chapters Capital Management first reported a position in Akebia Therapeutics in Q2 2015 and held it in 2 quarters.
  • Nine Chapters Capital Management's Akebia Therapeutics position peaked at $631K in Q2 2015.
  • 90 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2015.

Based on Nine Chapters Capital Management's 13F filing for Q4 2015.